NCT00544453View on ClinicalTrials.gov

Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

October 31, 2007

Study Completion Date

July 31, 2008

Conditions
Alzheimer Disease
Interventions
DRUG

[123I] MNI-308

Injection of \[123I\] MNI-308 and SPECT scanning

Trial Locations (1)

06510

Institute for Neurodegenerative Disorders, New Haven

Sponsors
All Listed Sponsors
lead

Molecular NeuroImaging

OTHER